798 related articles for article (PubMed ID: 28183310)
21. A Novel Letrozole Model Recapitulates Both the Reproductive and Metabolic Phenotypes of Polycystic Ovary Syndrome in Female Mice.
Kauffman AS; Thackray VG; Ryan GE; Tolson KP; Glidewell-Kenney CA; Semaan SJ; Poling MC; Iwata N; Breen KM; Duleba AJ; Stener-Victorin E; Shimasaki S; Webster NJ; Mellon PL
Biol Reprod; 2015 Sep; 93(3):69. PubMed ID: 26203175
[TBL] [Abstract][Full Text] [Related]
22. Adipocyte and steroidogenic cell cross-talk in polycystic ovary syndrome.
de Medeiros SF; Rodgers RJ; Norman RJ
Hum Reprod Update; 2021 Jun; 27(4):771-796. PubMed ID: 33764457
[TBL] [Abstract][Full Text] [Related]
23. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
[TBL] [Abstract][Full Text] [Related]
24. The effect of ellagic acid on sex hormones and miRNA-21 expression in rats with polycystic ovary syndrome.
Khoshvaghti A; Rahbari R
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4263-4273. PubMed ID: 38078918
[TBL] [Abstract][Full Text] [Related]
25. Photobiomodulation can improve ovarian activity in polycystic ovary syndrome-induced rats.
Alves ED; Bonfá ALO; Pigatto GR; Anselmo-Franci JA; Achcar JA; Parizotto NA; Montrezor LH
J Photochem Photobiol B; 2019 May; 194():6-13. PubMed ID: 30897401
[TBL] [Abstract][Full Text] [Related]
26. Androgens in polycystic ovary syndrome: lessons from experimental models.
Walters KA
Curr Opin Endocrinol Diabetes Obes; 2016 Jun; 23(3):257-63. PubMed ID: 26866639
[TBL] [Abstract][Full Text] [Related]
27. Letrozole treatment of pubertal female mice results in activational effects on reproduction, metabolism and the gut microbiome.
Arroyo P; Ho BS; Sau L; Kelley ST; Thackray VG
PLoS One; 2019; 14(9):e0223274. PubMed ID: 31568518
[TBL] [Abstract][Full Text] [Related]
28. Polycystic ovary morphology is associated with insulin resistance in women with polycystic ovary syndrome.
Hong SH; Sung YA; Hong YS; Jeong K; Chung H; Lee H
Clin Endocrinol (Oxf); 2017 Oct; 87(4):375-380. PubMed ID: 28543550
[TBL] [Abstract][Full Text] [Related]
29. Insulin and androgen relationships with abdominal body fat distribution in women with and without hyperandrogenism.
Pasquali R; Casimirri F; Cantobelli S; Labate AM; Venturoli S; Paradisi R; Zannarini L
Horm Res; 1993; 39(5-6):179-87. PubMed ID: 8314200
[TBL] [Abstract][Full Text] [Related]
30. Is foetal hyperexposure to androgens a cause of PCOS?
Filippou P; Homburg R
Hum Reprod Update; 2017 Jul; 23(4):421-432. PubMed ID: 28531286
[TBL] [Abstract][Full Text] [Related]
31. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria.
Jamil AS; Alalaf SK; Al-Tawil NG; Al-Shawaf T
Arch Gynecol Obstet; 2016 Feb; 293(2):447-56. PubMed ID: 26408006
[TBL] [Abstract][Full Text] [Related]
32. Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome.
Sahmay S; Atakul N; Oncul M; Tuten A; Aydogan B; Seyisoglu H
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):157-61. PubMed ID: 23806449
[TBL] [Abstract][Full Text] [Related]
33. Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome?
Catteau-Jonard S; Bancquart J; Poncelet E; Lefebvre-Maunoury C; Robin G; Dewailly D
Ultrasound Obstet Gynecol; 2012 Aug; 40(2):223-9. PubMed ID: 22648908
[TBL] [Abstract][Full Text] [Related]
34. High level of C-type natriuretic peptide induced by hyperandrogen-mediated anovulation in polycystic ovary syndrome mice.
Wang X; Wang H; Liu W; Zhang Z; Zhang Y; Zhang W; Chen Z; Xia G; Wang C
Clin Sci (Lond); 2018 Apr; 132(7):759-776. PubMed ID: 29535265
[TBL] [Abstract][Full Text] [Related]
35. Elevated androgens during puberty in female rhesus monkeys lead to increased neuronal drive to the reproductive axis: a possible component of polycystic ovary syndrome.
McGee WK; Bishop CV; Bahar A; Pohl CR; Chang RJ; Marshall JC; Pau FK; Stouffer RL; Cameron JL
Hum Reprod; 2012 Feb; 27(2):531-40. PubMed ID: 22114112
[TBL] [Abstract][Full Text] [Related]
36. Prostatic-specific antigen (PSA) levels in patients with polycystic ovary syndrome (PCOS): a meta-analysis.
Wu ZH; Tang Y; Niu X; Pu FF; Xiao XY; Kong W
J Ovarian Res; 2019 Oct; 12(1):94. PubMed ID: 31615559
[TBL] [Abstract][Full Text] [Related]
37. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest.
Jonard S; Dewailly D
Hum Reprod Update; 2004; 10(2):107-17. PubMed ID: 15073141
[TBL] [Abstract][Full Text] [Related]
38. Elevated circulating levels of secreted frizzled-related protein 4 in relation to insulin resistance and androgens in women with polycystic ovary syndrome.
Bicer M; Alarslan P; Guler A; Demir I; Aslanipour B; Calan M
J Endocrinol Invest; 2020 Mar; 43(3):305-313. PubMed ID: 31486991
[TBL] [Abstract][Full Text] [Related]
39. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age.
Alsamarai S; Adams JM; Murphy MK; Post MD; Hayden DL; Hall JE; Welt CK
J Clin Endocrinol Metab; 2009 Dec; 94(12):4961-70. PubMed ID: 19846740
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of visfatin by FK866 mitigates pathogenesis of cystic ovary in letrozole-induced hyperandrogenised mice.
Annie L; Gurusubramanian G; Roy VK
Life Sci; 2021 Jul; 276():119409. PubMed ID: 33781825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
